Diseases / Medulloblastoma
Medulloblastoma
DiseaseMedulloblastoma is a malignant embryonal tumor of the cerebellum and the most common malignant brain tumor in children. It can spread through cerebrospinal pathways and requires multimodal treatment.
- Trials
- 311
- Recruiting
- 36
- Completed
- 167
- With results
- 64
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Available | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 2 | 1 | — | 1 | 4 | 1 | — | — | — | — | — | 9 |
| Phase 1 | 13 | — | — | 9 | 73 | 12 | 7 | — | 5 | — | — | 119 |
| Phase 1/2 | 4 | 1 | — | 2 | 11 | 7 | — | 1 | 1 | — | — | 27 |
| Phase 2 | 6 | 1 | — | 16 | 44 | 5 | 2 | — | 6 | — | — | 80 |
| Phase 2/3 | — | — | — | 1 | 1 | — | — | — | — | — | — | 2 |
| Phase 3 | 2 | 1 | — | — | 8 | 2 | — | — | — | — | — | 13 |
| Phase 4 | 1 | — | — | 1 | — | — | — | — | — | — | — | 2 |
| Not applicable | 3 | 2 | — | — | 10 | 2 | 3 | — | 2 | — | — | 22 |
| Unknown | 5 | 5 | 1 | 1 | 16 | 2 | 1 | — | 4 | 1 | 1 | 37 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Medulloblastoma | 9 | 119 | 27 | 80 | 2 | 13 | 2 | 22 | 37 | 311 |
| Astrocytoma | 2 | 69 | 7 | 17 | — | 3 | — | 7 | 10 | 115 |
| Central Nervous System Neoplasms | 1 | 50 | 8 | 31 | — | 1 | 1 | 7 | 13 | 112 |
| Ependymoma | 2 | 40 | 9 | 33 | 1 | 2 | — | 9 | 16 | 112 |
| Glioma | 2 | 43 | 12 | 26 | — | 2 | — | 7 | 14 | 106 |
| Brain Neoplasms | 3 | 40 | 6 | 21 | 2 | 3 | — | 7 | 11 | 93 |
| Oligodendroglioma | — | 51 | 6 | 12 | — | 3 | — | 7 | 9 | 88 |
| Neuroblastoma | 1 | 29 | 11 | 30 | — | 3 | — | 4 | 6 | 84 |
| Familial ependymoma | 1 | 44 | 4 | 16 | — | 1 | — | 3 | 5 | 74 |
| Glioblastoma | 1 | 35 | 8 | 11 | — | 3 | — | 6 | 6 | 70 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Cancer Institute (NCI) | 53 | 0 |
| 2 | Children's Oncology Group | 18 | 5 |
| 3 | Pediatric Brain Tumor Consortium | 16 | 0 |
| 4 | St. Jude Children's Research Hospital | 11 | 0 |
| 5 | Giselle Sholler | 7 | 0 |
| 6 | Novartis Pharmaceuticals | 7 | 0 |
| 7 | Memorial Sloan Kettering Cancer Center | 6 | 0 |
| 8 | National Institutes of Health Clinical Center (CC) | 6 | 0 |
| 9 | City of Hope Medical Center | 5 | 0 |
| 10 | Duke University | 5 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Cyclophosphamide | 35 |
| 2 | Temozolomide | 33 |
| 3 | Etoposide | 26 |
| 4 | Filgrastim | 26 |
| 5 | Carboplatin | 25 |
| 6 | Cisplatin | 22 |
| 7 | Vincristine | 22 |
| 8 | Radiotherapy | 20 |
| 9 | Magnetic Resonance Spectroscopy | 18 |
| 10 | Thiotepa | 14 |
Evidence
- Results reported
- 38.3%64 of 167 completed
- Published
- 22.2%37 of 167 completed
- Primary endpoint met
- 57.1%4 of 7 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 33
- Median duration
- 68.9months
- Countries
- 34
- Study sites
- 1504
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 14
- Phase 1
- 26
- Phase 1/2
- 30
- Phase 2
- 42
- Phase 2/3
- 267
- Phase 3
- 130
- Phase 4
- 225
- Not applicable
- 33
- Unknown
- 145
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Houston | United States | 82 |
| 2 | New York | United States | 70 |
| 3 | Washington D.C. | United States | 69 |
| 4 | Chicago | United States | 66 |
| 5 | Memphis | United States | 61 |
| 6 | Philadelphia | United States | 60 |
| 7 | Pittsburgh | United States | 57 |
| 8 | Cincinnati | United States | 54 |
| 9 | Los Angeles | United States | 54 |
| 10 | Boston | United States | 53 |
Terminations
- Terminated
- 31
- Withdrawn
- 13
- Suspended
- 1
- Stopped for recruitment
- 4.8%15 of 311 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06639607 Suspended | Suspended | Drugs/Equipment Unavailable | 2051-06-30 |
| NCT07660458 Withdrawn | Withdrawn | Study withdrawn prior to enrollment due to administrative review | 2027-07-30 |
| NCT06466798 Withdrawn | Withdrawn | Inability to find participants meeting eligibility critieria | 2027-07-01 |
| NCT05934630 Terminated | Terminated | The NCI will not extend the PBTC grant beyond March 31, 2026. | 2026-04-17 |
| NCT00897286 Terminated | Terminated | New Protocol that replaces the current study | 2025-09-25 |
| NCT04402073 Terminated | Terminated | Poor accrual | 2025-09-10 |
| NCT03904862 Terminated | Terminated | The decision to permanently close PBTC-053 was made following communication from the NCI that the PBTC grant will not be extended beyond March 31, 2026. | 2025-08-11 |
| NCT03173950 Terminated | Terminated | Support was withdrawn from study resulting in early termination of study. Investigator had to close study due to no drug supply. | 2025-06-23 |
| NCT05429502 Terminated | Terminated | Study halted early due to high toxicity risk (from BHLRM model) in combo treatment and inability to identify recommended Phase 2 dose in initial phase (Phase 1-Part A), making continuation to subsequent phases (Phase 1-Part B and Phase 2) unfeasible. | 2025-02-26 |
| NCT04521946 Withdrawn | Withdrawn | No participants enrolled. | 2022-12-20 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: